What are the responsibilities and job description for the Senior / Principal Associate Scientist, In Vivo Pharmacology position at Dragonfly Therapeutics?
Senior / Principal Associate Scientist, In Vivo Pharmacology
Dragonfly Therapeutics seeks a highly skilled and experienced lab-based in vivo associate at the Senior Scientist to Principal Associate Scientist level to join our In Vivo team to support the advancement of our pre-clinical and clinical programs. The candidate must have extensive experience in the design, execution, and analysis of pre-clinical in vivo autoimmune disease and fibrosis models. Further expertise in ex vivo analysis techniques including flow cytometry, cell culture, and multiplex cytokine analysis is required. We are searching for an independent and flexible individual able to work efficiently across multiple projects. Final position level will be commensurate with experience.
Responsibilities (including but not limited to) :
- Design and execution of in vivo studies utilizing a variety of autoimmune and fibrosis models to independently conduct and analyze PKPD and Efficacy studies using small molecules and biologics. This position will also support oncology in vivo studies
- Utilize ex vivo analysis techniques (such as FACS, MSD / Luminex / AlphaLisa, cell culture, etc.) to understand the PD response and further elucidate disease biology
- Develop and validate multicolor flow cytometry panels and multiplex assays; troubleshoot and optimize assays as needed
- Maintain proper scientific documentation in an electronic lab notebook and ensure compliance with all safety and regulatory standards
- Generate, analyze, interpret, organize, and report experimental data
Qualifications :
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
Our mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes. We believe in a small team with a big impact.
